New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:49 EDTABMDAbiomed shares overvalued, says Northland Securities
Northland believes Abiomed utilization rates for Impella are going down on both the ImpellaCP and Impella 2.5. The firm said Abiomed's story is now dependent on new site add-ons where utilization rates haven moved and sees risk to shares. The firm rates Abiomed an Underperform with a $14 price target.
News For ABMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
07:07 EDTABMDAbiomed sees Q4 revenue $90M, consensus $85.11M
Subscribe for More Information
07:07 EDTABMDAbiomed raises FY16 revenue outlook to $326M from $305M-$315M
Subscribe for More Information
07:06 EDTABMDAbiomed reports Q3 EPS 23c, consensus 15c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use